Silo Pharma (SILO) Non Operating Investment Income (2013 - 2026)
Silo Pharma (SILO) posted Non Operating Investment Income of -$2060.0 for Q1 2026, down 308.29% sequentially from $989.0 in Q2 2025, and down 170.5% YoY from $2922.0 in Q1 2025.
Silo Pharma (SILO) Non Operating Investment Income (2013 - 2026) Analysis & Trends
Silo Pharma has reported Non Operating Investment Income for 9 years, with the latest figure at -$2060.0 in Q1 2026.
- Quarterly Non Operating Investment Income fell 170.5% year-over-year to -$2060.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1071.0 (down 164.4% YoY) and the FY2025 annual result came in at $3911.0, up 481.56% from the prior year.
- Non Operating Investment Income fell to -$2060.0 in Q1 2026 per SILO's latest filing, from $989.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $2922.0 in Q1 2025 and troughed at -$161798.0 in Q1 2022.
- A 5-year average of -$26932.3 and a median of -$1560.5 in 2023 frame the typical range for Non Operating Investment Income.
- The sharpest annual moves came in 2025 and 2026: Non Operating Investment Income surged 1148.72% in 2025, then slumped 170.5% in 2026.
- Over 5 years, Non Operating Investment Income stood at -$104700.0 in 2022, then soared by 98.22% to -$1862.0 in 2023, then jumped by 32.38% to -$1259.0 in 2024, then surged by 178.55% to $989.0 in 2025, then tumbled by 308.29% to -$2060.0 in 2026.
- According to Business Quant data, Non Operating Investment Income over the past three periods registered -$2060.0, $989.0, and $2922.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | -35,795.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,961.00 |
| Jun 30, 2026 | 4,961.00 |
| Mar 31, 2026 | -2,060.00 |
| Mar 31, 2026 | -2,060.00 |
| Jun 30, 2025 | 989.00 |
| Jun 30, 2025 | 989.00 |
| Mar 31, 2025 | 2,922.00 |
| Mar 31, 2025 | 2,922.00 |
| Jun 30, 2024 | -1,259.00 |
| Jun 30, 2024 | -1,259.00 |
| Mar 31, 2024 | 234.00 |
| Mar 31, 2024 | 234.00 |
| Sep 30, 2023 | -1,862.00 |
| Sep 30, 2023 | -1,862.00 |
| Jun 30, 2023 | -2,179.00 |
| Jun 30, 2023 | -2,179.00 |
| Mar 31, 2023 | 390.00 |
| Mar 31, 2023 | 390.00 |
| Jun 30, 2022 | -104,700.00 |
| Jun 30, 2022 | -104,700.00 |